title: A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.
abstract: Bispecific T-cell engagers (BiTEs) may break multiple barriers that currently limit the use of immunotherapy in glioblastoma patients. We have recently described a novel BiTE specific for a mutated form of the epidermal growth factor receptor, EGFRvIII, that exerts potent antineoplastic effects against established invasive tumors of the brain.
authors.affiliation: Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center; Durham, NC USA ; Department of Pathology; Duke University Medical Center; Durham, NC USA ; The Preston Robert Tisch Brain Tumor Center at Duke; Duke University Medical Center; Durham, NC USA.
authors.forename: Bryan D
authors.initials: BD
authors.lastname: Choi
authors.forename: Ira
authors.initials: I
authors.lastname: Pastan
authors.forename: Darell D
authors.initials: DD
authors.lastname: Bigner
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
keywords: T lymphocytes; bispecific antibodies; central nervous system neoplasms; epidermal growth factor receptor; immunotherapy